pCPA Activity Overview
Status | Total Negotiations | Summary |
---|---|---|
Active Negotiations | 44 | Non-oncology: 28 Oncology: 16 |
Under Consideration for Negotiation | 16 | Non-oncology: 10 Oncology: 6 |
Completed Negotiations | 729 | With Letter of Intent: 627 Without agreement: 102 |
Negotiations That Were Not Pursued | 108 |
pCPA Activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement Letters Issued in the last four weeks
Brand Name | Manufacturer | Indication | Engagement Date |
---|---|---|---|
Myalepta | Medison Pharma Canada Inc. | Leptin deficiency in lipodystrophy | |
Dupixent | Sanofi Genzyme Canada | Atopic dermatitis, pediatrics | |
Tecvayli | Janssen Inc. | Multiple myeloma, relapsed or refractory, in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progre | |
Elrexfio | Pfizer Canada ULC | Multiple myeloma, relapsed or refractory, in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progre | |
Imbruvica | Janssen Inc. | Chronic lymphocytic leukemia (CLL), in adult patients with previously untreated CLL, including those with 17p deletion | |
Tyenne | Fresenius Kabi Canada Ltd. | Multiple Indications | |
Imbruvica | Janssen Inc. | Waldenström's Macroglobulinemia |